AstraZeneca committed $2 billion to expand biologics manufacturing in Maryland, nearly doubling capacity at its Frederick site and building a new clinical-manufacturing facility in Gaithersburg. The company said the projects — operational by 2029 — will create or support roughly 2,600 jobs, including 300 specialized roles, and bring parts of its rare-disease portfolio onshore for the first time. AstraZeneca framed the investment as strengthening U.S. supply-chain resilience and accelerating clinical supply for innovative molecules; facilities will incorporate AI, automation, and sustainability features. The move follows a broader industry trend of large pharma boosting domestic biomanufacturing amid policy pressure to secure critical medicine supply.